in this issue
Regions :: Western Europe
Solvay Launches Bid to Buy Innogenetics
April 25, 2008 | Natasha Alperowicz
Solvay Pharmaceuticals says it plans to make a conditional tender offer to acquire the biotech company Innogenetics (Gent, Belgium) in a cash transaction valued at €5.75/share. Solvay initially entered into an R&D co-operation with Innogenetics in 1997 and has been implementing Innogenetics' technologies in its own drug discovery efforts. Solvay holds a 6.77% interest in Innogenetics. Solvay says it approves of Innogenetics'recent decision to divest its subsidiary GENimmune, which develops novel immune therapeutics, and to focus on diagnostics...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee